{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The Maximum Tolerated Dose (MTD) will be determined by first identifying the dose level at which \\>= 30% of patients experience a Dose Limiting Toxicity (DLT) according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, over a 28 day cycle. DLT will be defined based on the rate of drug-related grade 3-5, non-hematological adverse events experienced within the first 4 weeks (1 cycle) for each combined dosage scheme. The MTD will be defined as one dosage level below which DLT was observed in \\>= 30% of patients.","groups":[{"description":"Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg \\>75yrs) orally, days 1, 8,15, 22 of a 28 day cycle\n\nCombination therapy: Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.\n\nCycles will span 28 days. Dosage schedules will be:\n\n1. Everolimus daily for 28 days of a 28 day cycle;\n2. Pomalidomide daily for 21 days of a 28 day cycle\n3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle.","id":"OG000","title":"Combination Therapy"}],"populationDescription":"There was only one patient enrolled. The MTD could not be calculated based on one patient.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Maximum Tolerated Dosage (MTD)(Phase I)","type":"PRIMARY"}